SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Thursday reported a loss of $32.4 million in its fourth quarter.

On a per-share basis, the San Diego-based company said it had a loss of 27 cents.

The results matched Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for a loss of 27 cents per share.

The clinical-stage biotech company that develops stem cell treatments posted revenue of $1.4 million in the period.

For the year, the company reported a loss of $136.3 million, or $1.15 per share. Revenue was reported as $6.6 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE